Key result
Switching to the CNIC-polypill increased the proportion of patients with cardiovascular disease achieving blood pressure targets from 20.1% at baseline to 55.4% at 12 months (p < 0.001).
Why the study?
To evaluate the effectiveness of the CNIC-polypill in helping patients with cardiovascular disease achieve blood pressure goals.
Does the CNIC-polypill (acetylsalicylic acid, ramipril, simvastatin) improve achieving blood pressure goals in patients with a previous cardiovascular event?
Observational (n=572)
Yes
Does the CNIC-polypill (acetylsalicylic acid, ramipril, simvastatin) improve achieving blood pressure goals in patients with a previous cardiovascular event?
Absolute Event Rate: 55.4% vs 20.1%
p-value: p=<0.001
Switching to a polypill containing aspirin, ramipril, and simvastatin significantly improved blood pressure control in patients with established cardiovascular disease in routine practice.
May support polypill evaluation in secondary CVD prevention; leaves open need for RCTs to confirm and guide practice.
Aim: To determine the effectiveness of Centro Nacional de Investigaciones Cardiovasculares (CNIC)-polypill (acetylsalicylic acid 100 mg, ramipril 5/10 mg, simvastatin 40 mg) in achieving blood pressure (BP) goals. Patients & methods: A multicenter, observational, one cohort, prospective study. BP targets were analyzed in patients with cardiovascular disease after 12-months treatment with the CNIC polypill. Results: A total of 572 patients (59.4 ± 13.9 years, 57.3% men) were analyzed. At baseline, BP was 147.1 ± 18.1/88.3 ± 10.6 mmHg, 97.1% of patients were taken renin-angiotensin system inhibitors, 5.4% calcium antagonists, 1.9% diuretics and 13.1% β-blockers. The proportion of patients who achieved BP targets increased from 20.1 to 55.4% (p < 0.001). Conclusion: In routine practice, switching from usual care to the CNIC-polypill in patients with cardiovascular disease could facilitate achieving BP goals.
No takes yet. Share an insight, caveat, or question.
Gómez-Álvarez et al. (2019) conducted an observational in cardiovascular disease (n=572). CNIC-polypill vs. baseline was evaluated on achieving blood pressure (BP) goals (p=<0.001). Switching to the CNIC-polypill increased the proportion of patients with cardiovascular disease achieving blood pressure targets from 20.1% at baseline to 55.4% at 12 months (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: